Should spironolactone be switched to an angiotensin‑receptor‑neprilysin inhibitor (ARNI) such as sacubitril/valsartan in patients on dialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Should Spironolactone Be Switched to ARNI in Dialysis Patients?

No, do not routinely switch spironolactone to ARNI in dialysis patients—these medications serve different therapeutic purposes and are not interchangeable. Spironolactone is a mineralocorticoid receptor antagonist (MRA) used primarily for potassium management and additional neurohormonal blockade in heart failure, while ARNI (sacubitril/valsartan) provides renin-angiotensin system inhibition combined with neprilysin inhibition.

Understanding the Clinical Context

This question reflects a fundamental misunderstanding of guideline-directed medical therapy (GDMT) for heart failure. In patients with heart failure with reduced ejection fraction (HFrEF), the complete GDMT regimen includes ARNI (or ACEi/ARB), beta-blockers, MRAs, and SGLT2 inhibitors 1. These are complementary therapies, not alternatives to one another.

The Role of Each Medication

  • ARNI: Replaces ACEi or ARB as the foundation of renin-angiotensin system blockade. The 2022 AHA/ACC/HFSA guidelines strongly recommend switching from ACEi/ARB to ARNI in patients with chronic symptomatic HFrEF (NYHA class II-III) to reduce morbidity and mortality 2.

  • Spironolactone (MRA): Provides additional neurohormonal blockade through mineralocorticoid receptor antagonism. In dialysis patients, spironolactone up to 25 mg/day has been shown to be reasonably safe when properly monitored with a therapeutic algorithm for hyperkalemia management 3.

ARNI Use Specifically in Dialysis Patients

While major ARNI trials excluded dialysis patients, emerging real-world evidence supports its use in this population:

Efficacy Data

ARNI demonstrates meaningful benefits in dialysis patients with HFrEF:

  • Blood pressure reduction: In a randomized controlled multicenter study, ARNI reduced office systolic BP by 10.4 mmHg versus 4.6 mmHg with ARB (p=0.003), with even greater effects in hemodialysis patients (-15.9 mmHg vs -6.6 mmHg, p<0.05) 4.

  • Cardiac function improvement: Meta-analysis showed LVEF improvement of 4.61% (95% CI: 1.78%-7.44%) in ESRD patients, with benefits more pronounced at 12 months versus 6 months 5.

  • Mortality and hospitalization: A large propensity-matched study of 2,868 hemodialysis patients found ARNI associated with reduced all-cause mortality (HR 0.82,95% CI: 0.73-0.92) and all-cause hospitalization (HR 0.86,95% CI: 0.79-0.93) compared to ACEi/ARB 6.

Safety Profile

ARNI is generally well-tolerated in dialysis patients:

  • Decreased hyperkalemia risk compared to ACEi/ARB (HR 0.71,95% CI: 0.62-0.81) 6
  • No significant difference in hypotension rates 4, 6
  • Comparable safety profile to ARBs in multiple studies 7, 5

Dosing Considerations

Critical dosing guidance for dialysis patients 8:

  • Start at half the usual starting dose (24 mg/26 mg twice daily) in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²)
  • Titrate cautiously every 2-4 weeks as tolerated
  • Note: Only 14% of dialysis patients in one study achieved maximum dosing (97 mg/103 mg twice daily) 6

Clinical Decision Algorithm

For dialysis patients with HFrEF currently on spironolactone:

  1. Assess current RAAS blockade: Are they on ACEi or ARB?

    • If YES → Consider switching ACEi/ARB to ARNI (not replacing spironolactone)
    • If NO → Consider adding ARNI as de novo therapy

  2. Evaluate for ARNI contraindications 8:

    • History of angioedema (absolute contraindication)
    • Current ACEi use (requires 36-hour washout period)
    • Severe hepatic impairment (not recommended)

  3. If switching from ACEi/ARB to ARNI:

    • Allow 36-hour washout from last ACEi dose
    • Start at 24 mg/26 mg twice daily
    • Continue spironolactone (up to 25 mg/day with proper monitoring)
    • Monitor potassium, blood pressure, and symptoms closely

  4. Optimize complete GDMT regimen 1:

    • ARNI (or ACEi/ARB if ARNI contraindicated)
    • Beta-blocker
    • MRA (spironolactone)
    • SGLT2 inhibitor

Common Pitfalls to Avoid

  • Do not discontinue spironolactone when starting ARNI—they work synergistically through different mechanisms
  • Do not start ARNI without appropriate ACEi washout—risk of angioedema increases with concomitant use
  • Do not use standard starting doses—dialysis patients require dose reduction (start at 24 mg/26 mg twice daily)
  • Do not assume ARNI replaces all GDMT components—it only replaces ACEi/ARB, not MRAs or other therapies

Evidence Quality Considerations

The FDA label explicitly addresses dosing in severe renal impairment 8, and recent high-quality observational studies provide reassuring safety and efficacy data in dialysis populations 4, 6. However, randomized controlled trial data in dialysis patients remain limited, as these patients were excluded from landmark trials like PARADIGM-HF 2. The most robust dialysis-specific evidence comes from a 2024 propensity-matched study of nearly 3,000 patients 6 and a 2025 randomized controlled trial 4.

The appropriate clinical question should be: "Should ACEi/ARB be switched to ARNI in dialysis patients with HFrEF?"—and the answer is yes, with appropriate dose adjustment and monitoring, while maintaining spironolactone as part of comprehensive GDMT.

References

1
Guideline

kidney dysfunction in heart failure: core curriculum 2025.

American Journal of Kidney Diseases, 2025

Related Questions

What is the recommended sacubitril‑valsartan dosing schedule for an adult with end‑stage renal disease (CKD stage 5)?
In a dialysis patient with heart failure with reduced ejection fraction who is already taking spironolactone, should the angiotensin receptor‑neprilysin inhibitor sacubitril/valsartan be administered only twice daily?
Can Entresto (sacubitril/valsartan) be used in patients with chronic kidney disease?
Can I prescribe an angiotensin receptor neprilysin inhibitor (ARNI) such as sacubitril/valsartan in a patient with an estimated glomerular filtration rate of 27 mL/min/1.73 m²?
In a patient on chronic dialysis with heart failure with reduced ejection fraction, should low‑dose spironolactone be preferred over sacubitril/valsartan (an angiotensin receptor‑neprilysin inhibitor) for safety and mortality benefit?
In a patient on chronic dialysis with heart failure with reduced ejection fraction, should low‑dose spironolactone be preferred over sacubitril/valsartan (an angiotensin receptor‑neprilysin inhibitor) for safety and mortality benefit?
What is the differential diagnosis for a thumb injury caused by a volleyball ball that has resulted in limited range of motion?
In a trauma patient, can a maxillofacial CT scan detect intracranial hemorrhage?
In a dialysis patient with heart failure with reduced ejection fraction who is already taking spironolactone, should the angiotensin receptor‑neprilysin inhibitor sacubitril/valsartan be administered only twice daily?
What is the appropriate workup and management for a patient with severe shoulder pain, elevated C-reactive protein, and eosinophilia of about 16%?
Is there evidence that thioctic acid (alpha‑lipoic acid) improves neurologic recovery or overall outcomes in an adult with metastatic breast cancer who has spinal cord compression treated with radiation and has not regained motor strength?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.